SLC12A2

Across TCGA pan-cancer cohorts, SLC12A2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SLC12A2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SLC12A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC12A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, SCLC, and PAAD are the cancer types where SLC12A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
SCLC	OS	Median	IV	0.137	0.548	.004	18	view →
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →
UCEC	DFS	Median	All	0.769	0.631	.015	12	view →
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	12	view →
LUSC	DFS	Median	All	0.153	0.797	<.001	9	view →
OV	DFS	Median	III,IV	0.140	0.532	.002	6	view →
SARC	DFS	Median	All	0.094	0.632	<.001	3	view →
STAD	OS	Median	All	0.138	0.542	.048	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SLC12A2–CESC (DFS)

Open the CESC breakdown →